| Filed On | Filing |
|---|---|
| 22 Jan 2025 |
8-K/A: Financial Statements and Exhibits
New Brunswick, N.J. (January 22, 2025) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipelin... |
| 16 Apr 2024 |
8-K/A: Financial Statements and Exhibits
New Brunswick, N.J. (April 16, 2024) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2024. “Johnson & Johnson’s solid first quarter performance reflects our sharpened focus and the progress in our portfolio and ... |
| 15 Feb 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors New Brunswick, NJ (February 14, 2023) – Johnson & Johnson (NYSE: JNJ) announced today that Paula A. Johnson, MD, MPH, President of Welles... |
| 29 Aug 2017 |
8-K/A: Completion of Acquisition or Disposition of Assets
2Excludes amortization of intangible assets as presented separately. |
| 04 Aug 2008 |
8-K/A: Results of Operations and Financial Condition
On July 15, 2008, Johnson & Johnson issued the attached press release announcing its sales and earnings for the second quarter ended June 29, 2008. (Explanatory Note: The press release is incorporated by reference to Exhibit 99.15 of the... |
| 30 Nov 2007 |
8-K/A: Material Impairments; Other Events
On November 29, 2007, Johnson & Johnson (the "Company") announced that it will record a special after-tax, non-cash charge of approximately $440 million for the write-down of the intangible asset related to NATRECORr (nesiritide), a prod... |
| 02 Mar 2007 |
8-K/A: Completion of Acquisition or Disposition of Assets
COMBINED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2005 AND 2004 AND INDEPENDENT AUDITORS' REPORT THEREON |
| 30 Apr 2002 |
8-K/A: Other Events
2001 2000 1999 1998 1997 1996 Sales to customer- Domestic 19,825 17,316 15,532 12,901 11,814 10,851 Sales to customer- Int'l 12,492 11,856 11,825 10,910 10,708 10,536 Total Sales 32,317 29,172 27,357 23,811 22,522 21,387 Cost of products... |
| 30 Nov 2001 |
8-K/A: Other Events
Johnson & Johnson Completes Acquisition Of Inverness Medical Technology's Diabetes Care Products Business --------------------------------------- |
Loading...